377 related articles for article (PubMed ID: 28984489)
1. Directing the use of DDR kinase inhibitors in cancer treatment.
Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
3. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
Carrassa L; Colombo I; Damia G; Bertoni F
Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
5. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Brown JS; O'Carrigan B; Jackson SP; Yap TA
Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
[TBL] [Abstract][Full Text] [Related]
8. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Ngoi NYL; Westin SN; Yap TA
Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
[TBL] [Abstract][Full Text] [Related]
9. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
10. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
[No Abstract] [Full Text] [Related]
11. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of DNA Damage Response in Cancer.
Choi W; Lee ES
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
[TBL] [Abstract][Full Text] [Related]
13. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
14. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
15. DNA damage response as a therapeutic target in gynecological cancers.
Leary A; Auguste A; Mesnage S
Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
[TBL] [Abstract][Full Text] [Related]
16. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
17. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
Maresca L; Stecca B; Carrassa L
Cells; 2022 Apr; 11(9):. PubMed ID: 35563772
[TBL] [Abstract][Full Text] [Related]
19. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
20. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
